Clinically relevant drug–drug interactions between antiretrovirals and antifungals

Bibliography

• HHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2013;A1–4. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf
   Google Scholar
• Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. 2013. Available from: http://aidsinfo.nih.gov/contentfiles/adult_oi.pdf
   Google Scholar
• Centers for Disease Control and Prevention. Vital signs: HIV prevention through care and treatment–United States. MMWR Morb Mortal Wkly Rep 2011;60(47):1618-23
   PubMedGoogle Scholar
• Perbost I, Malafronte B, Pradier C, et al. In the era of highly active antiretroviral therapy, why are HIV-infected patients still admitted to hospital for an inaugural opportunistic infection? HIV Med 2005;6(4):232-9
   PubMed Web of Science ®Google Scholar
• Seal PS, Jackson DA, Chamot E, et al. Temporal trends in presentation for outpatient HIV medical care 2000-2010: implications for short-term mortality. J Gen Intern Med 2011;26(7):745-50
   PubMed Web of Science ®Google Scholar
• Bentwich Z. Concurrent infections that rise the HIV viral load. J HIV Ther 2003;8(3):72-5
   PubMedGoogle Scholar
• Lawn SD, Butera ST, Folks TM. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev 2001;14(4):753-77; table of contents
   PubMed Web of Science ®Google Scholar
• Warnock DW. Trends in the epidemiology of invasive fungal infections. Nihon Ishinkin Gakkai Zasshi 2007;48(1):1-12
   PubMedGoogle Scholar
• Tseng A, Foisy M. Important drug-drug interactions in HIV-infected persons on antiretroviral therapy: an update on new interactions between HIV and non-HIV drugs. Curr Infect Dis Rep 2012;14(1):67-82
   PubMedGoogle Scholar
• Moss JA. HIV/AIDS review. Radiol Technol 2013;84(3):247-67; quiz 68-70
   PubMedGoogle Scholar
• Engelman A, Cherepanov P. The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol 2012;10(4):279-90
   PubMed Web of Science ®Google Scholar
• Fanales-Belasio E, Raimondo M, Suligoi B, Butto S. HIV virology and pathogenetic mechanisms of infection: a brief overview. Ann Ist Super Sanita 2010;46(1):5-14
   PubMed Web of Science ®Google Scholar
• Flexner C. HIV drug development: the next 25 years. Nat Rev Drug Discov 2007;6(12):959-66
   PubMed Web of Science ®Google Scholar
• Haqqani AA, Tilton JC. Entry inhibitors and their use in the treatment of HIV-1 infection. Antiviral Res 2013;98(2):158-70
   PubMed Web of Science ®Google Scholar
• Bonora S, Calcagno A, Gonzalez de Requena D, et al. Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors. Infez Med 2006;14(2):61-70
   PubMedGoogle Scholar
• Back DJ, Burger DM, Flexner CW, Gerber JG. The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing. J Acquir Immune Defic Syndr 2005;39(Suppl 1):S1-23; quiz S24-5
   PubMed Web of Science ®Google Scholar
• Varatharajan L, Thomas SA. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res 2009;82(2):A99-109
   PubMed Web of Science ®Google Scholar
• Ruane PJ, DeJesus E. New nucleoside/nucleotide backbone options: a review of recent studies. J Acquir Immune Defic Syndr 2004;37(Suppl 1):S21-9
   PubMedGoogle Scholar
• Piliero PJ. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2004;37(Suppl 1):S2-S12
   PubMed Web of Science ®Google Scholar
• Usach I, Melis V, Peris JE. Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J Int AIDS Soc 2013;16(1):1-14
   PubMed Web of Science ®Google Scholar
• de Bethune MP. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res 2010;85(1):75-90
   PubMed Web of Science ®Google Scholar
• Ma Q, Okusanya OO, Smith PF, et al. Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opin Drug Metab Toxicol 2005;1(3):473-85
   PubMedGoogle Scholar
• Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 2001;40(12):893-905
   PubMed Web of Science ®Google Scholar
• Raffi F, Wainberg MA. Multiple choices for HIV therapy with integrase strand transfer inhibitors. Retrovirology 2012;9:110
   PubMedGoogle Scholar
• Malet I, Calvez V, Marcelin AG. The future of integrase inhibitors of HIV-1. Curr Opin Virol 2012;2(5):580-7
   PubMed Web of Science ®Google Scholar
• Adams JL, Greener BN, Kashuba AD. Pharmacology of HIV integrase inhibitors. Curr Opin HIV AIDS 2012;7(5):390-400
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Mathias AA, German P, Kearney BP. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet 2011;50(4):229-44
   PubMed Web of Science ®Google Scholar
• Patel M, Mandava NK, Vadlapatla RK, Mitra AK. Recent patents and emerging therapeutics for HIV infections: a focus on protease inhibitors. Pharm Pat Anal 2013;2(4):513-38
   Google Scholar
• Qiu X, Liu ZP. Recent developments of peptidomimetic HIV-1 protease inhibitors. Curr Med Chem 2011;18(29):4513-37
   PubMed Web of Science ®Google Scholar
• Pokorna J, Machala L, Rezacova P, Konvalinka J. Current and novel inhibitors of HIV protease. Viruses 2009;1(3):1209-39
   PubMed Web of Science ®Google Scholar
• Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012;Jul;308(4):387-402
   PubMed Web of Science ®Google Scholar
• Piacenti FJ. An update and review of antiretroviral therapy. Pharmacotherapy 2006;26(8):1111-33
   PubMed Web of Science ®Google Scholar
• Lawn SD, Torok ME, Wood R. Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections. Curr Opin Infect Dis 2011;24(1):34-42
   PubMed Web of Science ®Google Scholar
• Sax PE, Sloan CE, Schackman BR, et al. Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164. HIV Clin Trials 2010;11(5):248-59
   PubMed Web of Science ®Google Scholar
• Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009;4(5):e5575
   PubMed Web of Science ®Google Scholar
• Marty F, Mylonakis E. Antifungal use in HIV infection. Expert Opin Pharmacother 2002;3(2):91-102
   PubMedGoogle Scholar
• Pupaibool J, Limper AH. Other HIV-associated pneumonias. Clin Chest Med 2013;34(2):243-54
   PubMed Web of Science ®Google Scholar
• Ampel NM. Coccidioidomycosis in persons infected with HIV-1. Ann NY Acad Sci 2007;1111:336-42
   PubMed Web of Science ®Google Scholar
• Jarvis JN, Harrison TS. HIV-associated cryptococcal meningitis. Aids 2007;21(16):2119-29
   PubMed Web of Science ®Google Scholar
• Antinori S. New insights into HIV/AIDS-associated cryptococcosis. ISRN AIDS 2013;2013:471363
   PubMedGoogle Scholar
• Cassone A, Cauda R. Candida and candidiasis in HIV-infected patients: where commensalism, opportunistic behavior and frank pathogenicity lose their borders. AIDS 2012;26(12):1457-72
   PubMed Web of Science ®Google Scholar
• Ramos-e-Silva M, Lima CM, Schechtman RC, et al. Systemic mycoses in immunodepressed patients (AIDS). Clin Dermatol 2012;30(6):616-27
   PubMed Web of Science ®Google Scholar
• Chakrabarti A, Slavin MA. Endemic fungal infections in the Asia-Pacific region. Med Mycol 2011;49(4):337-44
   PubMed Web of Science ®Google Scholar
• Klepser M. The value of amphotericin B in the treatment of invasive fungal infections. J Crit Care 2011;26(2):225.e1-10
   PubMedGoogle Scholar
• Povoa P, Goncalves-Pereira J, Salluh JI. Amphotericin B in severe fungal infections: a critical reappraisal of the evidence. Am J Respir Crit Care Med 2013;188(8):1032
   PubMed Web of Science ®Google Scholar
• Vanden Bossche H, Engelen M, Rochette F. Antifungal agents of use in animal health–chemical, biochemical and pharmacological aspects. J Vet Pharmacol Ther 2003;26(1):5-29
   PubMed Web of Science ®Google Scholar
• Abuhammour W, Habte-Gabr E. Systemic antifungal agents. Indian J Pediatr 2001;68(7):655-68
   PubMedGoogle Scholar
• Lass-Florl C. Triazole antifungal agents in invasive fungal infections: a comparative review. Drugs 2011;71(18):2405-19
   PubMed Web of Science ®Google Scholar
• Diflucan (Fluconazole) Package Insert. Pfizer, Inc. New York, NY; 2013
   Google Scholar
• Sporanox (Itraconazole) Package Insert. Janssen Pharmaceuticals, Inc., Titusville, NJ; 2012
   Google Scholar
• Scheinfeld N. Ketoconazole: a review of a workhorse antifungal molecule with a focus on new foam and gel formulations. Drugs Today (Barc) 2008;44(5):369-80
   PubMed Web of Science ®Google Scholar
• Stevens DA. Advances in systemic antifungal therapy. Clin Dermatol 2012;30(6):657-61
   PubMed Web of Science ®Google Scholar
• Mikulska M, Novelli A, Aversa F, et al. Voriconazole in clinical practice. J Chemother 2012;24(6):311-27
   PubMed Web of Science ®Google Scholar
• Vfend (Voriconazole) Package Insert. Pfizer, Inc., New York, NY; 2011
   Google Scholar
• Walker LA, Gow NA, Munro CA. Fungal echinocandin resistance. Fungal Genet Biol 2010;47(2):117-26
   PubMed Web of Science ®Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet 2003;362(9390):1142-51
   PubMed Web of Science ®Google Scholar
• Kauffman CA, Carver PL. Update on echinocandin antifungals. Semin Respir Crit Care Med 2008;29(2):211-19
   PubMed Web of Science ®Google Scholar
• Eschenauer G, Depestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk Manag 2007;3(1):71-97
   PubMedGoogle Scholar
• Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis 2006;43(2):215-22
   PubMed Web of Science ®Google Scholar
• Dowell JA, Knebel W, Ludden T, et al. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004;44(6):590-8
   PubMed Web of Science ®Google Scholar
• McCormack PL, Perry CM. Caspofungin: a review of its use in the treatment of fungal infections. Drugs 2005;65(14):2049-68
   PubMed Web of Science ®Google Scholar
• Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006;42(8):1171-8
   PubMed Web of Science ®Google Scholar
• Jarvis B, Figgitt DP, Scott LJ. Micafungin. Drugs 2004;64(9):969-82; discussion 83- 4
   PubMed Web of Science ®Google Scholar
• Josephson F. Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition. J Intern Med 2010;268(6):530-9
   PubMed Web of Science ®Google Scholar
• Pal D, Kwatra D, Minocha M, et al. Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals. Life Sci 2011;88(21-22):959-71
   PubMed Web of Science ®Google Scholar
• Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol 2006;1(3):323-39
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010;9(3):215-36
   PubMed Web of Science ®Google Scholar
• Pelkonen O, Turpeinen M, Hakkola J, et al. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 2008;82(10):667-715
   PubMed Web of Science ®Google Scholar
• Jana S, Paliwal J. Molecular mechanisms of cytochrome p450 induction: potential for drug-drug interactions. Curr Protein Pept Sci 2007;8(6):619-28
   PubMed Web of Science ®Google Scholar
• Vadlapatla RK, Vadlapudi AD, Pal D, Mitra AK. Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes. Curr Pharm Des 2013;19(40):7126-40
   PubMed Web of Science ®Google Scholar
• Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001;344(13):984-96
   PubMed Web of Science ®Google Scholar
• Fuzeon (Enfuvirtide) Package Insert. Genentech USA, Inc., South San Francisco, CA; 2013
   Google Scholar
• Joly V, Jidar K, Tatay M, Yeni P. Enfuvirtide: from basic investigations to current clinical use. Expert Opin Pharmacother 2010;11(16):2701-13
   PubMed Web of Science ®Google Scholar
• Makinson A, Reynes J. The fusion inhibitor enfuvirtide in recent antiretroviral strategies. Curr Opin HIV AIDS 2009;4(2):150-8
   PubMed Web of Science ®Google Scholar
• Patel IH, Zhang X, Nieforth K, et al. Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet 2005;44(2):175-86
   PubMed Web of Science ®Google Scholar
• Hyland R, Dickins M, Collins C, et al. Maraviroc: in vitro assessment of drug-drug interaction potential. Br J Clin Pharmacol 2008;66(4):498-507
   PubMed Web of Science ®Google Scholar
• Abel S, Russell D, Taylor-Worth RJ, et al. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008;65(Suppl 1):27-37
   PubMed Web of Science ®Google Scholar
• Selzentry (Maraviroc) Package Insert. ViiV Healthcare; Research Triangle Park, NC; 2013
   Google Scholar
• Walker DK, Abel S, Comby P, et al. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos 2005;33(4):587-95
   PubMed Web of Science ®Google Scholar
• Viread (Tenofovir disoproxil fumarate) Package Insert. Gilead Sciences, Inc., Foster City, CA; 2013
   Google Scholar
• Retrovir (Zidovudine) Package Insert. GlaxoSmithKline, Research Triangle Park, NC: 2013
   Google Scholar
• Rescriptor (Delavirdine mesylate) Packge Insert. ViiV Healthcare, Research Triangle Park, NC; 2012
   Google Scholar
• Sustiva (Efavirenz) Package Insert. Bristol-Myers Squibb, Princeton, NJ; 2013
   Google Scholar
• Koo HL, Hamill RJ, Andrade RA. Drug-drug interaction between itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis. Clin Infect Dis 2007;45(6):e77-9
   PubMed Web of Science ®Google Scholar
• Krishna G, Moton A, Ma L, et al. Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers. J Acquir Immune Defic Syndr 2009;51(4):437-44
   PubMed Web of Science ®Google Scholar
• Sriwiriyajan S, Mahatthanatrakul W, Ridtitid W, Jaruratanasirikul S. Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV-infected patients. Eur J Clin Pharmacol 2007;63(5):479-83
   PubMed Web of Science ®Google Scholar
• Damle B, LaBadie R, Crownover P, Glue P. Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. Br J Clin Pharmacol 2008;65(4):523-30
   PubMed Web of Science ®Google Scholar
• Tivicay (Dolutegravir) Package Insert. GlaxoSmithKline, Research Triangle Park, NC; 2013
   Google Scholar
• Isentress (Raltegravir) Package Insert. Merck & Co., Inc., Whitehouse Station, NJ; 2013
   Google Scholar
• Chapman TM, Plosker GL, Perry CM. Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection. Drugs 2004;64(18):2101-24
   PubMed Web of Science ®Google Scholar
• Lexiva (Fosamprenavir calcium) Package Insert. GlaxoSmithKline, Research Triangle Park, NC; 2013
   Google Scholar
• Polk RE, Crouch MA, Israel DS, et al. Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men. Pharmacotherapy 1999;19(12):1378-84
   PubMed Web of Science ®Google Scholar
• Bruggemann RJ, van Luin M, Colbers EP, et al. Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers. J Antimicrob Chemother 2010;65(10):2188-94
   PubMed Web of Science ®Google Scholar
• Norvir (Ritonavir) Package Insert. AbbVie, Inc., North Chicago, IL; 2013
   Google Scholar
• Kaletra (Lopinavir/Ritonavir) Package Insert. AbbVie, Inc., North Chicago, IL; 2013
   Google Scholar
• Liu P, Foster G, Gandelman K, et al. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother 2007;51(10):3617-26
   PubMed Web of Science ®Google Scholar
• Kredo T, Van der Walt JS, Siegfried N, Cohen K. Therapeutic drug monitoring of antiretrovirals for people with HIV. Cochrane Database Syst Rev 2009;(3):CD007268
   PubMed Web of Science ®Google Scholar
• Gerber JG, Acosta EP. Therapeutic drug monitoring in the treatment of HIV-infection. J Clin Virol 2003;27(2):117-28
   PubMed Web of Science ®Google Scholar
• Ziagen (Abacavir sulfate) Package Insert. GlaxoSmithKline, Research Triangle Park, NC; 2013
   Google Scholar
• Videx EC (Didanosine) Package Insert. Bristol-Myers Squibb, Princeton, NJ; 2012
   Google Scholar
• Emtriva (Emtricitabine) Package Insert. Gilead Sciences, Inc., Foster City, CA; 2012
   Google Scholar
• Epivir (Lamivudine) Package Insert. GlaxoSmithKline, Research Triangle Park, NC; 2013
   Google Scholar
• Zerit (Stavudine) Package Insert. Bristol-Myers Squibb, Princeton, NJ; 2012
   Google Scholar
• Intelence (Etravirine) Package Insert. Janssen Pharmaceuticals, Inc., Titusville, NJ; 2013
   Google Scholar
• Viramune (Nevirapine) Package Insert. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT; 2013
   Google Scholar
• Jaruratanasirikul S, Sriwiriyajan S. Pharmacokinetic study of the interaction between itraconazole and nevirapine. Eur J Clin Pharmacol 2007;63(5):451-6
   PubMed Web of Science ®Google Scholar
• Edurant (Rilpivirine) Package Insert. Janssen Therapeutics, Titusville, NJ; 2013
   Google Scholar
• Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate) Package Insert. Gilead Sciences, Inc., Foster City, CA; 2013
   Google Scholar
• Reyataz (Atazanavir sulfate) Package Insert. Bristol-Myers Squibb, Princeton, NJ; 2013
   Google Scholar
• Prezista (Darunavir) Package Insert. Janssen Pharmaceuticals, Inc., Titusville, NJ; 2013
   Google Scholar
• Sekar VJ, Lefebvre E, De Pauw M, et al. Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers. Br J Clin Pharmacol 2008;66(2):215-21
   PubMed Web of Science ®Google Scholar
• Crixivan (Indinavir sulfate) Package Insert. Merck & Co., Inc., Whitehouse Station, NJ; 2012
   Google Scholar
• Viracept (Nelfinavir mesylate) Package Insert. Agouron Pharmaceuticals, Inc., La Jolla, CA; 2013
   Google Scholar
• Invirase (Saquinavir mesylate) Package Insert. Genentech USA, Inc., South San Francisco, CA; 2012
   Google Scholar
• Koks CH, van Heeswijk RP, Veldkamp AI, et al. Itraconazole as an alternative for ritonavir liquid formulation when combined with saquinavir. AIDS 2000;14(1):89-90
   PubMed Web of Science ®Google Scholar
• MacKenzie-Wood AR, Whitfeld MJ, Ray JE. Itraconazole and HIV protease inhibitors: an important interaction. Med J Aust 1999;170(1):46-7
   PubMed Web of Science ®Google Scholar
• Kaeser B, Zandt H, Bour F, et al. Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir. Antimicrob Agents Chemother 2009;53(2):609-14
   PubMed Web of Science ®Google Scholar
• la Porte CJ, Sabo JP, Elgadi M, Cameron DW. Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers. Antimicrob Agents Chemother 2009;53(1):162-73
   PubMed Web of Science ®Google Scholar
• Aptivus (Tipranavir) Package Insert. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT; 2012
   Google Scholar